1746-28-7

Basic information

• Product Name: 4-BROMOPHENETHYL BROMIDE
• Synonyms: 4-BROMOPHENETHYL BROMIDE;4-BROMO-1-(2-BROMOETHYL)BENZENE;1-BROMO-4-(2-BROMOETHYL)BENZENE;1-Bromo-4-(2-bromoethyl)benzene, 4-Bromo-1-(2-bromoethyl)benzene;Benzene, 1-broMo-4-(2-broMoethyl)-;2-(4-BroMophenyl)ethyl broMide;4-BroMophenethyl broMide 96%;4-Bromophenethylebromide
• CAS NO: 1746-28-7
• Molecular Formula: C₈H₈Br₂
• Molecular Weight: 263.96
• Product Categories: Aromatic Halides (substituted)
• Mol File: 1746-28-7.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 97-98.5 °C1 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: Colorless to yellow/Liquid or Low Melting Solid
• Density: 1.7272 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0128mmHg at 25°C
• Refractive Index: n20/D 1.5954(lit.)
• Storage Temp.: 2-8°C
• Solubility: Acetonitrile (Slightly), Chloroform (Sparingly), Dichloromethane (Slightly)
• CAS DataBase Reference: 4-BROMOPHENETHYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOPHENETHYL BROMIDE(1746-28-7)
• EPA Substance Registry System: 4-BROMOPHENETHYL BROMIDE(1746-28-7)

Safety Data

• Hazard Codes: Xn,N
• Statements: 22-51/53
• Safety Statements: 60-61
• RIDADR: UN 3082 9/PG 3
• WGK Germany: 2
• Hazardous Substances Data: 1746-28-7(Hazardous Substances Data)

Usage

General Description

4-Bromophenethyl bromide is a chemical compound with the molecular formula C8H8Br2. It is commonly used as an alkylating agent in organic synthesis and pharmaceutical research. This colorless liquid is known for its ability to react with nucleophiles to form a wide range of organic compounds. It is also utilized in the preparation of other bromo compounds and as a reactant in the synthesis of biologically active compounds. Additionally, 4-Bromophenethyl bromide has been studied for its potential use as a therapeutic agent in treating various diseases and disorders. However, it is important to handle this chemical with caution, as it is hazardous and can cause skin and eye irritation, as well as lung damage if inhaled.

InChI:InChI=1/C8H8Br2/c9-6-5-7-1-3-8(10)4-2-7/h1-4H,5-6H2

Upstream product

• 4654-39-1 4-bromophenethanol 
• 99-73-0 para-bromophenacyl bromide 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 16532-79-9 4-Bromophenylacetonitrile 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 106-37-6 1.4-dibromobenzene 
• 214614-36-5 1-(piperidin-4-yl)-6-acetamidomethylindole 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 1585-07-5 1-bromo-4-ethylbenzene 
• 3240-34-4 [bis(acetoxy)iodo]benzene 
• 64-19-7 acetic acid 
• 106-41-2 4-bromo-phenol 
• 106-93-4 ethylene dibromide 
• 114369-15-2 2-(4-bromophenyl)ethyl methanesulfonate 

Downstream Products

• 132352-76-2 O-(2-(4-bromophenyl)ethyl) acetohydroxamate 
• 132352-75-1 O-(2-(4-bromophenyl)ethyl) benzohydroxamate 
• 88999-92-2 2-(4-bromophenyl)ethane-1-thiol 
• 23703-22-2 1-bromo-4-n-hexylbenzene 
• 1382354-33-7 2-{3-(4-bromophenethoxy)phenylamino}benzamide 
• 1403621-01-1 ethyl 13-(4-bromophenyl)tridecanoate 
• 1403619-49-7 (4-bromophenylethyl) diphenylphosphine 

Relevant articles and documents

Enantioselective Copper(I)/Chiral Phosphoric Acid Catalyzed Intramolecular Amination of Allylic and Benzylic C?H Bonds

Radical-involved enantioselective oxidative C?H bond functionalization by a hydrogen-atom transfer (HAT) process has emerged as a promising method for accessing functionally diverse enantioenriched products, while asymmetric C(sp3)?H bond amination remains a formidable challenge. To address this problem, described herein is a dual CuI/chiral phosphoric acid (CPA) catalytic system for radical-involved enantioselective intramolecular C(sp3)?H amination of not only allylic positions but also benzylic positions with broad substrate scope. The use of 4-methoxy-NHPI (NHPI=N-hydroxyphthalimide) as a stable and chemoselective HAT mediator precursor is crucial for the fulfillment of this transformation. Preliminary mechanistic studies indicate that a crucial allylic or benzylic radical intermediate resulting from a HAT process is involved.

Preparation method for hemihydrate lorcaserin hydrochloride

The invention discloses a preparation method for hemihydrate lorcaserin hydrochloride. The preparation method comprises the following steps: (1) making a compound shown as a formula III react with ammonia to obtain a compound shown as a formula II; (2) under the protection of nitrogen gas, dissolving the compound shown as the formula II in an organic solvent, adding a hydrogen chloride solution of which the solvent is the organic solvent to salify, and adding water and cyclohexane to form a hemihydrate in order to obtain the compound shown as a formula I, wherein the organic solvent is isopropanol or 1,4-dioxane. In the preparation method disclosed by the invention, ammonium hydroxide substitutes for potassium carbonate in the prior art, so that unqualified ignition residues of a finial product caused by potassium chloride generated after salt removal can be avoided; an isopropoxide hydrochloride solution substitutes for the conventional hydrogen chloride gas, so that other impurities can be prevented from being introduced in a preparation process under the improper control of dosage and rate of the gas.

Diamino triazines derivatives, their salts, preparation method, composition and use thereof

The invention discloses derivatives and salts of damino dihydrotriazine, and a preparation method, a composition and application thereof. According to the invention, the preparation method of the damino dihydrotriazine derivative and the damino dihydrotriazine salt can be realized by adopting a method I or a method II, wherein the method I includes the step of obtaining a general formula I compound prepared through the reaction between a general formula IV compound and a general formula V compound, while the method II includes the step of mixing a general formula VIII compound with a general formula II compound under an acidic condition, and obtaining the compound shown in the general formula I through a cyclization reaction of the mixture. The invention also provides application of derivatives and salts of the damino dihydrotriazine in preparation of human dihydrofolate reductase inhibitors, preventing and curing drugs for tumor or bacterial infection diseases. The invention further provides a drug composition, which comprises an effective amount of the derivatives and/or salts of the damino dihydrotriazine, as well as pharmaceutically acceptable carriers. According to the invention, spiro heterocyclic ring derivatives of the damino dihydrotriazine have an excellent inhibitory activity on human dihydrofolate reductase, tumor cells and bacteria.